TY - JOUR
T1 - Incident Substance Use Disorder Following Anxiety Disorder in Privately Insured Youth
AU - Bushnell, Greta A.
AU - Gaynes, Bradley N.
AU - Compton, Scott N.
AU - Dusetzina, Stacie B.
AU - Olfson, Mark
AU - Stürmer, Til
N1 - Funding Information:
Research reported in this publication was supported by the National Institute of Mental Health (Bethesda, MD) under Award Number F31MH107085 (G.A.B.) and under T32MH013043. The funding source had no role in the study design; collection, analysis and interpretation of data; writing of the report; and decision to submit the article for publication. The database infrastructure was funded by the Department of Epidemiology, UNC Gillings School of Global Public Health, the Cecil G. Sheps Center for Health Services Research, UNC, the CER Strategic Initiative of UNC's Clinical Translational Science Award (UL1TR002489), and the UNC School of Medicine. Author contribution: G.A.B. authored the first draft of the article.
Funding Information:
Research reported in this publication was supported by the National Institute of Mental Health (Bethesda, MD) under Award Number F31MH107085 (G.A.B.) and under T32MH013043. The funding source had no role in the study design; collection, analysis and interpretation of data; writing of the report; and decision to submit the article for publication. The database infrastructure was funded by the Department of Epidemiology, UNC Gillings School of Global Public Health, the Cecil G. Sheps Center for Health Services Research, UNC, the CER Strategic Initiative of UNC's Clinical Translational Science Award (UL1TR002489), and the UNC School of Medicine. Conflicts of interest: B.N.G., S.B.D., and M.O. report no financial interests or potential conflicts of interest. G.A.B. received research support from the National Institute of Mental Health (Bethesda, MD) under Award Number F31MH107085 (G.A.B.) and under T32MH013043. T.S. receives investigator-initiated research funding and support as Principal Investigator (R01 AG056479) from the National Institute on Aging (NIA) and as Co-Investigator (R01 CA174453; R01 HL118255, R21-HD080214), National Institutes of Health (NIH). He also receives salary support as Director of Comparative Effectiveness Research (CER), NC TraCS Institute, UNC Clinical and Translational Science Award (UL1TR002489), the Center for Pharmacoepidemiology (current members: GlaxoSmithKline, UCB BioSciences, Merck, Shire), and from pharmaceutical companies (Amgen, AstraZeneca, Novo Nordisk) to the Department of Epidemiology, University of North Carolina at Chapel Hill. T.S. does not accept personal compensation of any kind from any pharmaceutical company. He owns stock in Novartis, Roche, BASF, AstraZeneca, and Novo Nordisk. S.N.C. receives research support from the National Institute of Mental Health, NC GlaxoSmithKline Foundation, Mursion, Inc. and has been a consultant for Shire, received honoraria from the Journal of Consulting and Clinical Psychology, Nordic Long-Term OCD Treatment Study Research Group, and The Centre for Child and Adolescent Mental Health, Eastern and Southern Norway, and given expert testimony for Duke University.
Funding Information:
Research reported in this publication was supported by the National Institute of Mental Health (Bethesda, MD) under Award Number F31MH107085 (G.A.B.) and under T32MH013043 . The funding source had no role in the study design; collection, analysis and interpretation of data; writing of the report; and decision to submit the article for publication. The database infrastructure was funded by the Department of Epidemiology, UNC Gillings School of Global Public Health , the Cecil G. Sheps Center for Health Services Research , UNC, the CER Strategic Initiative of UNC's Clinical Translational Science Award (UL1TR002489), and the UNC School of Medicine .
Publisher Copyright:
© 2019 Society for Adolescent Health and Medicine
PY - 2019/10
Y1 - 2019/10
N2 - Purpose: Anxiety disorders in childhood might be associated with an increased risk of substance use disorders. Incident substance use–related diagnoses were quantified in the 2 years after youth were newly diagnosed with an anxiety disorder and in a similar cohort of youth without diagnosed anxiety. Methods: Privately insured youth (10–17 years) were identified in a commercial claims database who were newly diagnosed with an anxiety disorder (2005–2014), treatment naïve, and without baseline substance-related disorder diagnoses. The comparison cohort included age, sex, region, and date matched youth with equivalent baseline exclusions. We used Kaplan–Meier estimator to calculate 2-year cumulative incidence of substance use disorder diagnosis following a new office-based anxiety disorder diagnosis (or match date for comparison cohort). Results: In 131,271 youth with a new anxiety disorder diagnosis (male = 41%, median age = 14 years), 1.5% (95% confidence interval = 1.5–1.6) had an incident substance use disorder diagnosis 1 year after their anxiety diagnosis, 2.9% (95% confidence interval = 2.8–3.0) by 2 years. Over the same period, .5% and 1.1% of the comparison cohort had incident substance use disorder diagnoses (n = 1,321,701). In the anxiety cohort, 2-year incidence was higher in youth aged 14–17 years (4.6%) versus 10–13 years (.7%). Incidence of substance use diagnosis varied by anxiety disorder (e.g., 2-year incidence: 4.3% for post-traumatic stress disorder, 3.0% for generalized anxiety disorder). Conclusion: Approximately 3% of youth newly diagnosed with anxiety received an incident substance use disorder diagnosis within 2 years, almost threefold the incidence in youth without an anxiety diagnosis, emphasizing the need for increased awareness and prevention of substance-related disorders in pediatric anxiety.
AB - Purpose: Anxiety disorders in childhood might be associated with an increased risk of substance use disorders. Incident substance use–related diagnoses were quantified in the 2 years after youth were newly diagnosed with an anxiety disorder and in a similar cohort of youth without diagnosed anxiety. Methods: Privately insured youth (10–17 years) were identified in a commercial claims database who were newly diagnosed with an anxiety disorder (2005–2014), treatment naïve, and without baseline substance-related disorder diagnoses. The comparison cohort included age, sex, region, and date matched youth with equivalent baseline exclusions. We used Kaplan–Meier estimator to calculate 2-year cumulative incidence of substance use disorder diagnosis following a new office-based anxiety disorder diagnosis (or match date for comparison cohort). Results: In 131,271 youth with a new anxiety disorder diagnosis (male = 41%, median age = 14 years), 1.5% (95% confidence interval = 1.5–1.6) had an incident substance use disorder diagnosis 1 year after their anxiety diagnosis, 2.9% (95% confidence interval = 2.8–3.0) by 2 years. Over the same period, .5% and 1.1% of the comparison cohort had incident substance use disorder diagnoses (n = 1,321,701). In the anxiety cohort, 2-year incidence was higher in youth aged 14–17 years (4.6%) versus 10–13 years (.7%). Incidence of substance use diagnosis varied by anxiety disorder (e.g., 2-year incidence: 4.3% for post-traumatic stress disorder, 3.0% for generalized anxiety disorder). Conclusion: Approximately 3% of youth newly diagnosed with anxiety received an incident substance use disorder diagnosis within 2 years, almost threefold the incidence in youth without an anxiety diagnosis, emphasizing the need for increased awareness and prevention of substance-related disorders in pediatric anxiety.
KW - Adolescent
KW - Anxiety disorders
KW - Child
KW - Substance-related disorders
UR - http://www.scopus.com/inward/record.url?scp=85068979857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068979857&partnerID=8YFLogxK
U2 - 10.1016/j.jadohealth.2019.05.007
DO - 10.1016/j.jadohealth.2019.05.007
M3 - Article
C2 - 31326248
AN - SCOPUS:85068979857
SN - 1054-139X
VL - 65
SP - 536
EP - 542
JO - Journal of Adolescent Health
JF - Journal of Adolescent Health
IS - 4
ER -